At 28 years old, Mary Beth Ballard received a bladder cancer diagnosis that would change her life. After getting the news and seeking multiple opinions, doctors at Vanderbilt University Medical Center were able to optimizing KARL STORZ Blue Light Cystoscopy with Cysview (BLCC) to clearly identify her cancer cells and remove them. Thanks to this technology, Mary Beth Ballard is now cancer free and advocates for the tool that gave her hope. Find out more about how BLCC is saving lives through her story.
* Cysview® is an optical imaging agent indicated for use in the cystoscopic detection of non-muscle invasive bladder cancer including carcinoma in situ (CIS) among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy. Cysview® is used with the KARL STORZ Photodynamic Diagnostic (PDD) system to perform Blue Light Cystoscopy (BLC) as an adjunct to the white light cystoscopy.
Published
November 8, 2019
Created by
